Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Xilio Therapeutics, Inc.NASDAQ: XLO

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 578.0% from a year ago

Total equity stood at $72.55M at the end of Q1 FY2026, up 578.0% from a year earlier and up 105.7% from the prior quarter. Over 3 fiscal years it compounded at -30.6% a year.

Context

  • Total equity amounted to 44.4% of total assets at the end of Q1 FY2026, up 34.1 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +578.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$72.55M+105.7% QoQ
Last fiscal yearDec 2025
$35.27M+100.4% YoY
Year agoMar 2025
$10.7M+578.0% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+578.0%——
1 year+100.4%——
3-year CAGR-30.6%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
35.27M USD
Year-over-year change
+100.4%
4-year CAGR
-34.0%

Total Equity vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's Mar 2026 total equity of $72.55M is the 2nd highest of the 4 companies compared; the peer median is $30.3M.
  • Its year-over-year change of +578.0% is the highest of 4, against a peer median of +59.4%.
  • Total equity amounts to 44.4% of total assets for XLO, versus a peer median of 75.5%.
XLO Competitors Peer median
Total Equity for XLO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OKUROnKure Therapeutics, Inc.Mar 2026$184.35M +103.4%—92.8%
XLOXilio Therapeutics, Inc.Mar 2026$72.55M +578.0%-30.6%44.4%
ATNMActinium Pharmaceuticals, Inc.Jun 2026$30.3M +59.4%-51.0%75.5%
PDSBPDS Biotechnology CorporationMar 2026$3.89M -82.6%-40.5%15.8%
Peer median (excluding XLO) $30.3M+59.4%-45.8%75.5%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents198.05M120.39M44.7M55.29M137.53M
Short-term Investments00000
Net Receivables00005M
Inventory00000
Other Current Assets4.46M4.11M3.42M4.94M2.5M
Total Current Assets202.52M124.5M48.13M60.23M145.03M
Property, Plant & Equipment (Net)13.9M12.84M11.2M9.06M7.85M
Goodwill00000
Intangible Assets00000
Long-term Investments1.55M1.56M01.78M1.81M
Tax Assets3.54M0000
Other Non-current Assets90K267K1.6M00
Total Non-current Assets19.08M14.67M12.8M10.84M9.66M
Total Assets221.6M139.17M60.93M71.08M154.69M
Account Payables3.14M3.13M1.05M2.57M3.17M
Short-term Debt883K6.67M3.32M00
Tax Payables00000
Deferred Revenue00013.52M40.02M
Other Current Liabilities3.61M82K6.9M4.21M5.73M
Total Current Liabilities12.78M21.12M15.96M27.26M56.27M
Long-term Debt9.63M3.17M000
Deferred Tax Liabilities3.54M0000
Deferred Revenue (Non-current)00019.26M0
Other Non-current Liabilities045K0057.53M
Total Non-current Liabilities23.39M12.4M8.14M26.22M63.14M
Total Liabilities36.17M33.52M24.1M53.48M119.41M
Common Stock3K3K3K5K36.89M
Retained Earnings(160.89M)(249.11M)(325.51M)(383.75M)(418.79M)
Accumulated OCI00000
Other Stockholders Equity0000417.17M
Minority Interest00000
Total Equity185.43M105.65M36.83M17.6M35.27M
Total Debt20.74M19.94M11.46M8.14M6.95M
Net Debt(177.32M)(100.45M)(33.25M)(47.15M)(130.58M)

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.